WASHINGTON, D.C. — Federal regulators have cleared the way for certain pancreatic cancer patients to access an experimental drug earlier than usual, approving a rapid pathway that allows treatment outside traditional clinical trials.
What This Means for You
- Some advanced pancreatic cancer patients may access a new drug early
- Doctors can request treatment for eligible patients outside trials
- The drug is still under review and not yet fully approved
The U.S. Food and Drug Administration issued a “safe to proceed” letter allowing Revolution Medicines to launch an expanded access treatment protocol for its investigational drug daraxonrasib.
Expanded access, sometimes called “compassionate use,” allows patients with serious or life-threatening conditions to receive experimental treatments when no other options are available and they cannot participate in clinical trials.
Who Is Eligible
The program targets patients with metastatic pancreatic ductal adenocarcinoma, an advanced form of pancreatic cancer that has already been treated but continues to progress.
Physicians licensed in the United States must submit requests to the drug’s sponsor on behalf of eligible patients.
Rapid FDA Review
The FDA received the request on April 28 and authorized it on April 30, completing the review in two days.
“Granting the request two days after receiving the expanded access application reflects the FDA’s strong commitment to facilitate early access to therapies for serious and life-threatening conditions,” said Commissioner Marty Makary.
How the Drug Works
Daraxonrasib is designed to target RAS, a protein that is commonly mutated in pancreatic cancer tumors and plays a key role in driving cancer growth.
By inhibiting this protein, the drug aims to slow or stop tumor progression.
Regulatory Status and Next Steps
The drug remains under development and has not yet received full FDA approval.
Revolution Medicines has indicated it plans to submit a new drug application through the agency’s National Priority Voucher pilot program, which is intended to accelerate review of promising therapies.
The FDA has already granted the drug Breakthrough Therapy designation, which is reserved for treatments that may offer substantial improvement over existing options, as well as Orphan Drug designation, which supports development of therapies for rare diseases.
The expanded access program will operate alongside ongoing clinical development as regulators continue to evaluate the drug’s safety and effectiveness.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.